Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

Bullboard (GREY:ATBPF)

View:
Prev ... 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ... Next
Comment by StockingUp21on Dec 17, 2022 10:15am

RE:RE:RE:RE:RE:RE:RE:Upcoming ...

Bad luck opinion or setting up for soft landing   
226
Discussion
Comment by MrMugsyon Dec 15, 2022 6:26pm

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Upcoming ...

Yes ... the 346 and 352 head-2-head is interesting but like everything else ... it's still comes with a whole lot of confusion. For example, I know 352 has always been Ketoprofen based. But, I ...more  
404
Discussion
Post by Duster340on Dec 15, 2022 2:27pm

2023 could be good/ if they put it all together

{^youtubevideo|(width)425|(height)264|(rel)False|(url)https://www.bnnbloomberg.ca/video/there-s-going-to-be-a-lot-more-m-a-in-the-biotech-space-in-2023-frances-horodelski~2565435|(fs)True|(loop)False| ...more  
247
Comment by Benedictuson Dec 15, 2022 8:13am

RE:RE:RE:RE:RE:RE:RE:RE:RE:Upcoming ...

  Yes and hopefully the quarterly burn rate is a little lower with acute than chronic. I appreciated Dan stressing their intention toward financial prudence. Capital is obviously extremely hard ...more  
224
Discussion
Comment by MrMugsyon Dec 14, 2022 12:43am

RE:RE:RE:RE:RE:RE:RE:RE:Upcoming ...

I agree Benedictus ... I'm just kidding. By the end of 2022, we'll have $42.5 MM in the bank and we need a minimum of 2 years runway. We also need cash on hand to pay for specialists as ...more  
291
Discussion
Comment by Benedictuson Dec 13, 2022 11:01pm

RE:RE:RE:RE:RE:RE:RE:Upcoming ...

  Mugs, I always appreciate your insights and optimism but a share buyback threat would have been an awful bluff and a tell of inept management.  They need every damn penny on hand and ...more  
201
Discussion
Comment by MrMugsyon Dec 13, 2022 4:23pm

RE:RE:RE:RE:RE:RE:Upcoming ...

Hahaha - I don't think it works that way but I could be wrong. I think he covered some future capital gains on the sale of Antibe Holdings - but - maybe I'm wrong.  I would have done ...more  
213
Discussion
Comment by woundedkneeon Dec 13, 2022 3:58pm

RE:RE:RE:RE:RE:Upcoming ...

About time for Dan to sell some more of his shares. Christmas bills coming up. lol
96
Discussion
Comment by MrMugsyon Dec 13, 2022 2:36pm

RE:RE:RE:RE:Upcoming ...

Yes - a couple points on Nuance First, Nuance will likely own all rights to OTENA ... be it acute and/or chronic Second, there are some wording issues in the agreement for ATE/Nuance to figure out ...more  
251
Discussion
Comment by nobeardon Dec 12, 2022 7:21pm

RE:RE:RE:Upcoming ...

Has there been any mention of Nunance and how they might fit into this?
100
Discussion
Comment by MrMugsyon Dec 11, 2022 5:05pm

RE:RE:Upcoming ...

Biggest conflict I've paid attention to w.r.t FDA is the Biogen AD drug and how professionals started quitting FDA one by one after Aduhelm was approved - even after all 10 said "do not pass ...more  
339
Discussion
Comment by Wriggleson Dec 11, 2022 11:19am

RE:RE:Upcoming ...

Your point is well taken about big pharma and their state politicians attempting to influence FDA decisions, in general.  In this case, I recall that the AME study was conducted under the ...more  
232
Discussion
Comment by Inthepezon Dec 11, 2022 10:42am

RE:RE:Upcoming ...

Or have a (previous) FDA insider who knows the right people. One would assume Stauffer will play a bigger role down the line. 
149
Discussion
Comment by woundedkneeon Dec 11, 2022 9:49am

RE:Upcoming ...

A bit off topic, but i just finished watching an episode from Tucker Carlson Today, interviewing Dr. Aeem Malhotra from the UK. The main theme of his talk is why the covid vacinnes are dangerous and ...more  
252
Discussion
Post by Duster340on Dec 09, 2022 9:13am

RE:RE:Defamatory Statement Suggesting Insider Trading ?

in davgro's world insiders do not share information with there family, and politicians do not buy and sell stock on first hand information. by the way this is 100% legal
194
Prev ... 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities